ObjectiveTo investigate the treatment outcome and safety of levofloxacin-containing in treating intensive phase treatment pulmonary tuberculosis accompanied with diabetes mellitus. MethodsOne hundred and twenty-four pulmonary tuberculosis accompanied with diabetes mellitus were randomly divided into observation group and control group,with 62 cases in each group. All patients received anti-tuberculosis treatment of 2-3HRZE/4-6HR, and observation group received levofloxacin in treatment enhancement period. Sputum smears, examination results of lung CT and adverse reaction between the two groups were compared after treatment for 3 months, 6 months, 9 months. ResultsAfter treatment for 3 months, the sputum negative conversion rate , lesions absorption rate and tuberculosis cavities occlusion rate in observation group were 82.26%, 75.81% and 77.42%, respectively, which were significantly higher than those in the control group (58.06%, 53.23%, 51.61% respectively, P＜0.05). However, no significant differences were found in the sputum negative conversion rate , lesions absorption rate and tuberculosis cavities occlusion rate between two groups after treatment for 6 months 6 and 9 months (P＞0.05). There were also no significant differences in incidence of adverse events between two groups (P＞0.05). ConclusionsLevofloxacin-containing in treating intensive phase treatment pulmonary tuberculosis accompanied with diabetes mellitus is safe,which can shorten the time of the negative transformation of sputum bacterium and promote lesions absorption, and worth to be widely used.

无